GI Cell·HK Innoen, Joint Research on Allogeneic CAR-NK Therapeutic Candidate

[Asia Economy Reporter Lee Gwan-joo] GI Cell and HK Innoen announced on the 29th that they have signed a joint research and development agreement for allogeneic CAR-NK candidate substances.

Through this agreement, both companies will initiate the development of multiple CAR-NK therapies, and if successful in deriving candidate substances and producing preclinical samples, they plan to discuss further development including clinical development and commercialization.

GI Cell has secured related technology, including successfully achieving the world's first large-scale mass culture of NK cells at 200ℓ using a bioreactor in February this year. HK Innoen possesses capabilities in innovative drug development such as K-CAB and is developing various pipelines.

Joo Sung-yoo, CSO of GI Cell, said, "The allogeneic NK cells developed by our company prevent NK cell exhaustion by regulating the binding affinity of cytokine receptors during the culture process, and have dramatically increased the efficiency of CAR gene introduction in NK cells, which are generally known to be more difficult to express genes in than T cells, thereby entering the leading group in the CAR-NK field."

Won Sung-yong, Director of the Bio Research Institute at HK Innoen, stated, "We are driving the development of immune-oncology cell therapies through joint research with various companies that possess technological competitiveness in the cell therapy field. Through this joint research and development with GI Cell, we plan to secure a CAR-NK pipeline with great growth potential in the future."

This content was produced with the assistance of AI translation services.